Search Results 1041-1050 of 17499 for Assay

1. A Study to Evaluate Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced Melanoma - Mayo Clinic

   Patient must have BRAF V600E or BRAF V600K tumor genotype based on a Clinical Laboratory Improvement Act (CLIA) approved assay. Patient must have measurable ...

2. Cholangiocarcinoma Clinical Trials - Mayo Clinic Research

   cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR) Rochester, MN. The purpose of this ...

3. A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Note: If there is proper documentation of an undetectable drug level measured by a commercially available assay for any of the approved biologics above ...

4. Alzheimer's Disease Clinical Trials - Mayo Clinic Research

   The purpose of this study is to validate the Alzheimer Disease Biomarkers assays (Phospho-Tau/Total-Tau/Ab42) being implemented at Mayo to compare them to the ...

5. Laboratories - Mayo Clinic Research

   Sort by: Faculty · Areas of Research · active Find a program led by a researcher whose last name begins with the letter A A · Find a program led by a ...

6. Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects with Moderate to Severe Crohn's Disease - Mayo Clinic

   Inclusion Criteria: Diagnosis of Crohn's disease (CD) for at least 90 days, confirmed by endoscopy during the Screening Period.

7. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

   Tumor PD-L1 status, confirmed by a reference laboratory using the Ventana SP263 PD-L1 immunohistochemistry (IHC) assay, must be known prior to randomization.

8. A Study to Assess LXH254 in Patients with Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma - Mayo Clinic

   Documentation of BRAFV600 or NRAS mutation in tumor tissue prior to study treatment as determined by local assay or as determined by central pre-screening ...

9. Publications - Sophie Bersoux, M.D., M.P.H. - Mayo Clinic

   ... assay to quantify eosinophil degranulation from patient-derived sources. J Immunol Methods. 2012 Oct 31; 384 (1-2):10-20 Epub 2012 June 28. View PubMed ...

10. Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant - Mayo Clinic

    ... assays. Willing to comply with the protocol; Females of child-bearing potential must have a negative pregnancy test (serum β-HCG) and sexually active females ...